IMCR Immunocore Holdings plc ADRs

Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$48.21  +1.50 (3.21%)
As of 03/27/2023 13:04:10 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  02/04/2021
Outstanding shares:  45,303,698
Average volume:  202,617
Market cap:   $2,145,583,137
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BLCD809

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%